Benzinga | Nov 13, 2020 06:21AM EST

HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Raises Price Target to $64

HC Wainwright & Co. maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target from $62 to $64.